Using our deep-rooted understanding of oncology discovery, we can add significant value to your project by expediting its progression through your discovery pipeline, from Target Validation through to Lead Optimisation and candidate nomination. Sygnature Discovery has an excellent track record of delivery in the oncology field, delivering 4 clinical candidates since 2011.
Our experienced scientists have developed a comprehensive discovery and translational oncology platform to allow efficient design, characterisation and development of your novel compounds using physiologically relevant systems.
Our broad oncology platform coupled with our extensive capabilities in Chemistry, DMPK, Computational Chemistry provide Sygnature with the necessary capabilities to support the most challenging oncology projects.
Our scientists work in close collaboration with you to generate flexible custom in vitro screening cascades, implementing state-of-the-art technologies and platforms across a variety of cell culture formats including 3D spheroids, scaffolds, primary cells and co-cultures.
Oncology Platform Highlights
We have a range of in vitro assays readily available to support your oncology programs, including: